arrow
M

Maksim Mamonkin

baylor college of medicine
H指数:25
被引数:3,805

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

国际共识指南:关于AML CAR T细胞临床研究的实施与报告

2025-08-210
OAAI
Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

同种免疫防御受体与粘附配体CD58的遗传剔除相结合是一种促进异基因细胞疗法功能持久性的综合方法,无需条件性化疗。

BLOOD
IF23.1
2024-11-050
PRE
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity

嵌合抗原受体诱导的抗原丢失可保护CD5.CART细胞免受自杀性杀伤,而不会损害靶向细胞毒性

2024-07-012
OAAI
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies

CD7-unedited CD7 CAR T细胞治疗T细胞恶性肿瘤的可行性和临床前疗效

2023-01-0135
OAAI
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

儿童和青少年癌症患者嵌合抗原受体T细胞药物产品开发儿科战略论坛与欧洲药品管理局合作,食品和药物管理局参与加速

2022-01-0127
OA
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

靶向HER2和IL13Rα2的串联CAR T细胞减轻肿瘤抗原逃逸

2021-07-019
OA
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia

调节tnf α 活性允许CLL-1 car-t细胞的转基因IL15-Expressing安全地消除急性髓细胞性白血病

2020-09-1634
OAAI
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Expression of Concern of Vol 126, Pg 3036, 2016)

靶向HER2和IL13Rα2的串联CAR T细胞减轻肿瘤抗原逃逸 (Vol 126的关注表达,3036页,2016页)

2019-07-0222
OA